Literature DB >> 24429657

Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.

Ziba Rahbar1, Maryam Daneshpazhooh1, Mostafa Mirshams-Shahshahani1, Nafiseh Esmaili1, Kazem Heidari2, Nessa Aghazadeh1, Pardis Hejazi1, Mahsa Ghajarzadeh2, Cheyda Chams-Davatchi1.   

Abstract

IMPORTANCE: Recently, the clinical pemphigus disease activity indexes of Pemphigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), and Pemphigus Vulgaris Activity Score (PVAS) were validated to correlate with physician global assessment. The antidesmoglein (anti-Dsg) autoantibodies are known to correlate mostly with pemphigus disease activity. The correlation between these indexes and anti-Dsg1 and anti-Dsg3 enzyme-linked immunosorbent assay values has not been previously evaluated.
OBJECTIVES: To evaluate the PDAI, ABSIS, and PVAS in a large number of patients with pemphigus vulgaris and to compare the interrater reliability of these indexes and the convergent validity according to anti-Dsg values. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study was performed in 2012 in a referral university center for autoimmune bullous diseases. One hundred patients with confirmed diagnoses of pemphigus vulgaris and clinical pemphigus lesions (mean [SD] age, 43.3 [1.7] years; age range, 14-77 years; female-male ratio, 1:3) were studied. Three dermatologists familiar with immunobullous diseases and the indexes rated the patients.
INTERVENTIONS: All 100 patients were evaluated with the PDAI, ABSIS, and PVAS. Three dermatologists independently rated all 3 indexes for each of the patients on the same day. Serum anti-Dsg1 and anti-Dsg3 enzyme-linked immunosorbent assay values were measured simultaneously. MAIN OUTCOMES AND MEASURES: Analyses of interrater reliabilities, convergent validities according to anti-Dsg titers, correlation between the distribution and types of lesions with disease activity, predictors of higher titers of antibody (multiple regression analysis), and cutoff values of measures for 2 titers of anti-Dsg with optimal area under the curve, sensitivity, and specificity were performed.
RESULTS: The interrater reliabilities were highest for the PDAI, followed by the ABSIS and the PVAS (intraclass correlation coefficients of 0.98 [95% CI, 0.97-0.98], 0.97 [95% CI, 0.96-0.98], and 0.93 [95% CI, 0.90-0.95], respectively). The convergent validity was highest for the PDAI, followed by the PVAS and the ABSIS (Spearman ρ = 0.67, 0.52, and 0.33, respectively). Head, neck, and trunk involvement were predictors of higher titers of anti-Dsg1. CONCLUSIONS AND RELEVANCE: Among the 3 studied indexes, the PDAI had the highest validity and is recommended for use in multicenter studies for rare diseases, such as pemphigus vulgaris.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24429657     DOI: 10.1001/jamadermatol.2013.8175

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  11 in total

Review 1.  Pemphigus vulgaris: an evidence-based treatment update.

Authors:  Cathy Y Zhao; Dedee F Murrell
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index.

Authors:  R L Krain; C E Bax; S Chakka; S Ahmed; R Feng; A S Payne; V P Werth
Journal:  Br J Dermatol       Date:  2021-02-01       Impact factor: 9.302

3.  The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus.

Authors:  Marta Sar-Pomian; Marta Kurzeja; Lidia Rudnicka; Malgorzata Olszewska
Journal:  An Bras Dermatol       Date:  2014 Nov-Dec       Impact factor: 1.896

Review 4.  Validation studies of outcome measures in pemphigus.

Authors:  Sarah Hanna; Minhee Kim; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2016-12-10

Review 5.  The Significance of Scalp Involvement in Pemphigus: A Literature Review.

Authors:  Marta Sar-Pomian; Lidia Rudnicka; Malgorzata Olszewska
Journal:  Biomed Res Int       Date:  2018-03-25       Impact factor: 3.411

6.  Rituximab therapy improves recalcitrant Pemphigus vulgaris.

Authors:  Pedram Noormohammadpour; Amirhooshang Ehsani; Hossein Mortazavi; Maryam Daneshpazhooh; Kamran Balighi; Mohammad Mofidi; Fatemeh Gholamali; Ali Sadeghinia
Journal:  EXCLI J       Date:  2015-01-21       Impact factor: 4.068

Review 7.  Management of pemphigus vulgaris: challenges and solutions.

Authors:  Stamatis Gregoriou; Ourania Efthymiou; Christina Stefanaki; Dimitris Rigopoulos
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-21

8.  Scalp involvement in pemphigus: a prognostic marker.

Authors:  Marta Sar-Pomian; Marek Konop; Kamila Gala; Lidia Rudnicka; Malgorzata Olszewska
Journal:  Postepy Dermatol Alergol       Date:  2017-11-08       Impact factor: 1.837

9.  Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity.

Authors:  Naiyu Lin; Qingxiu Liu; Menglei Wang; Qian Wang; Kang Zeng
Journal:  PeerJ       Date:  2018-08-03       Impact factor: 2.984

10.  Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.

Authors:  Rebecca L Krain; Carolyn J Kushner; Meera Tarazi; Rebecca G Gaffney; Andrea C Yeguez; Danielle E Zamalin; David R Pearson; Rui Feng; Aimee S Payne; Victoria P Werth
Journal:  Front Immunol       Date:  2019-11-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.